61 completed, 16 unknown, 13 recruiting, 13 terminated. 64 Phase 1, 52 Phase 2, 9 Not applicable, 4 Phase 3.
Follow Acute Lymphocytic Leukemia: new trials by email Literature Review of Acute Lymphocytic Leukemia trials Research Report on Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) Treatment with A319 - Acute Lymphocytic Leukemia | Not applicable | Not yet recruiting | Shanxi Bethune Hospital | 18 | 2026-02-02 | 2026-01-28 |
| Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Haplo-Identical / Cord Blood Transplant - aGVHD, Acute Myelogenous Leukemia | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 36 | 2025-08-13 | 2026-09-15 |
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL CAR19TIF cells, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-06-20 | 2025-06-25 |
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-02-15 | 2026-05-08 |
| A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. Acute Lymphocytic Leukemia | Active not recruiting | Pfizer | 12 | 2024-11-07 | 2026-09-25 | |
| A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors chimeric antigen receptor gene modified T cells - Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin | Not applicable | Recruiting | Shanxi Bethune Hospital | 45 | 2023-12-01 | 2025-01-20 |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. - Hematologic Malignancy, Leukemia | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-11-15 | 2026-10-01 | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Naoyuki G. Saito, M.D., Ph.D. | 2023-10-01 | 2023-12-11 | |
| Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors KT-253 - Myeloid Malignancies, Acute Lymphocytic Leukemia | Phase 1 | Completed | Kymera Therapeutics, Inc. | 52 | 2023-05-15 | 2025-01-27 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Pilot Imaging Study of Leukemia FLT - Acute Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Oklahoma | 60 | 2023-01-19 | 2026-04-23 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy Inotuzumab ozogamicin - Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 31 | 2022-10-18 | 2026-04-16 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | Beijing Boren Hospital | 2022-05-10 | 2026-10-15 | |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. LP-118 - Non Hodgkin Lymphoma, Richter Transformation | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 100 | 2022-05-08 | 2026-05-05 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 33 | 2022-04-28 | 2023-02-14 |
| A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia LCAR-AIO Cells - Acute Lymphocytic Leukemia | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2022-03-14 | 2025-06-03 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy Duvelisib, CAR T-cells - Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | Active not recruiting | Washington University School of Medicine | 42 | 2022-02-28 | 2026-09-24 |
Showing 20 of 117. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (117) · Leukemia, Myeloid, Acute (66) · Myelodysplastic Syndromes (39) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (36) · Lymphoma, Non-Hodgkin (36) · Leukemia (25) · Multiple Myeloma (23) · Lymphoma (22) · Hodgkin Disease (21) · Anemia, Refractory, with Excess of Blasts (13) · Burkitt Lymphoma (12) · Lymphoma, Mantle-Cell (12) · Lymphoma, Follicular (11) · Primary Myelofibrosis (10)
Hemic and Lymphatic Diseases (117) · Immune System Diseases (117) · Neoplasms by Histologic Type (117) · Hematologic Diseases (116) · Immunoproliferative Disorders (116) · Lymphatic Diseases (116) · Lymphoproliferative Disorders (115) · Neoplasms (115) · Leukemia, Lymphoid (114) · Leukemia (92) · Leukemia, Myeloid (66) · Pathologic Processes (60) · Pathological Conditions, Signs and Symptoms (60) · Disease Attributes (58) · Bone Marrow Diseases (57)
Cyclophosphamide (27) · fludarabine (24) · fludarabine phosphate (15) · Whole-Body Irradiation (12) · Mycophenolic Acid (11) · Busulfan (10) · Tacrolimus (10) · Granulocyte Colony-Stimulating Factor (8) · Methotrexate (8) · Melphalan (7) · Filgrastim (6) · Vincristine (5) · Clofarabine (4) · Cyclosporine (4) · Cytarabine (4)
Masonic Cancer Center, University of Minnesota (7) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Pfizer (3) · Traws Pharma, Inc. (3) · Washington University School of Medicine (3) · Baylor College of Medicine (2) · Callisto Pharmaceuticals (2) · Case Comprehensive Cancer Center (2) · Chinese PLA General Hospital (2) · Indiana University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Loyola University (2) · Medical College of Wisconsin (2)
United States (84) · China (17) · Canada (7) · France (3) · Egypt (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Israel (1) · Saudi Arabia (1) · Spain (1)
Helen Heslop, MD (2) · Leland Metheny, MD (2) · Mark Minden, MD (2) · Mary Horowitz, MD, MS (2) · Nirali N Shah, M.D. (2) · Robert Nelson, MD (2) · A. John Barrett, M.D. (1) · Alaa El-Hadad, PhD (1) · Amir A Toor, MD (1) · Armin Ghobadi, M.D. (1) · Ashwin Gollerkeri, MD (1) · Barton Kamen, MD (1) · Beata Holkova, MD (1)
PMID 23524640, PMID 34515338, PMID 34687939, PMID 37486616, PMID 12011123, PMID 13679531, PMID 18997171, PMID 19706886, PMID 21684344, PMID 21993685, PMID 22009536, PMID 22133778, PMID 22422826, PMID 23065508, PMID 24777753, PMID 24782509, PMID 25354103, PMID 25682597, PMID 27400247, PMID 28054442, PMID 29144985, PMID 29248669, PMID 29296758, PMID 30389035, PMID 30668890, PMID 31518304, PMID 31699827, PMID 32023374, PMID 32286905, PMID 33231879, PMID 33475736, PMID 33666654, PMID 33822526, PMID 33869653, PMID 34156874, PMID 34273598, PMID 34309174, PMID 34889384, PMID 35126471, PMID 35435984, PMID 35605184, PMID 35622074, PMID 36084276, PMID 36402456, PMID 37088401, PMID 37120135, PMID 37295816, PMID 38170741, PMID 38238616, PMID 38376944
U24CA076518 (2), 2018 (1), 2023 (1), K12CA167540 (1), P30CA072720 (1), RC2CA148431 (1), U01HL069294 (1), U10HL069294 (1)